Table 1.
Clinical trials of CMT in stage I or II Hodgkin lymphoma
FFDP indicates freedom from disease progression; INT, Istituto Nazionale Tumori; and NS, not significant.
*Comparison of PFS for 4ABVD + 20 Gy IFRT vs 4ABVD + 30 Gy IFRT.
Clinical trials of CMT in stage I or II Hodgkin lymphoma
FFDP indicates freedom from disease progression; INT, Istituto Nazionale Tumori; and NS, not significant.
*Comparison of PFS for 4ABVD + 20 Gy IFRT vs 4ABVD + 30 Gy IFRT.
